Drug Profile
G 238
Alternative Names: G-238Latest Information Update: 22 Mar 2016
Price :
$50
*
At a glance
- Originator SALVAT
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ear disorders; Mycoses
Most Recent Events
- 22 Mar 2016 No recent reports on development identified - Phase-III for Otomycosis in Spain (Otic)
- 01 Nov 2014 Salvat completes a phase III trial in Mycoses (Otomycosis) in Spain (Otic, drops) (NCT01993823)
- 31 May 2013 Phase-III clinical trials in Ear disorders (otomycosis) in Spain (Otic)